-
Integra LifeSciences (IART) PT Raised to $22 at Citi
-
Citi Downgrades Integra LifeSciences (IART) to Sell
-
Citi Reiterates Neutral Rating on Integra LifeSciences (IART)
-
Citi Upgrades Integra LifeSciences (IART) to Neutral
-
Integra LifeSciences (IART) plunges after product recall
-
Citi Downgrades Integra LifeSciences (IART) to Sell, Sees Revenue Impact of $60M and EPS Impact of $0.35
-
Integra LifeSciences Announces Participation in Upcoming Investor Conferences
-
Citi Starts Integra LifeSciences (IART) at Neutral
-
Integra LifeSciences (IART) PT Raised to $61 at Citi
-
Integra LifeSciences (IART) PT Lowered to $54.50 at Citi
-
Integra LifeSciences (IART) PT Lowered to $60 at Citi
-
Citi Downgrades Integra LifeSciences (IART) to Neutral
-
Integra LifeSciences (IART) PT Raised to $64 at Citi
-
Pre-Open Stock Movers 01/11: (BIOC) (DSCI) (ENPH) Higher; (NVDQ) (ETH) (SIG) Lower (more...)
-
Citi Starts Integra LifeSciences (IART) at Buy
-
Integra LifeSciences to Participate in the 2014 Citi Global and RBC Capital Markets Healthcare Conferences in February
-
Citi Defends Integra LifeSciences (IART); Says Sell-Off Overdone
-
Citi Upgrades Integra LifeSciences (IART) to Buy
-
George Soros' Hedge Fund Slashes Stake In Gold ETF (GLD), Raises Stake in Citi (C) and AT&T (T)
-
Citi Maintains a 'Hold' on Integra Lifesciences Holdings (IART); Model Update for Recent Debt Changes
-
Highlights On Integra Lifesciences (IART) From Citi's Healthcare Conference; M&A, Euro Exposure, And Asia Expansion,
-
Citi Maintains a 'Hold' on Integra Lifesciences Holdings (IART); Highlights from Meetings with Management at AANS
-
Morning Movers 1/09: Palm (PALM) Jumps On Pre Intro; CVS (CVS) Lower On Guidance

